CloudMD: Canaccord Lowers Target After Leading $55 Million Bought Deal

On March 9th, CloudMD Software & Services (TSXV: DOC)  announced that their C$55 million bought deal financing closed, with underwriters taking an additional 1.9 million shares equal to C$5.1 million.

CloudMD currently has five analysts covering the company with a weighted 12-month price target of C$3.82. This is down from last month, which was C$3.91. One analyst has a strong buy rating, while the other four have buy ratings on the name.

The street high comes from Laurentian Bank with a C$4.25 price target, and the lowest target comes from Canaccord Genuity with a C$3.50 price target. Laurentian Bank raised their price target from C$4 to C$4.25 while Canaccord downgraded the name from C$3.75 to C$3.50 after they both were a part of the underwriting, with Canaccord Genuity actually leading the underwriting.

Cambria Gold Mines — sponsored Sponsored · Cambria Gold Mines

Doug Taylor, Canaccord’s analyst, reiterated his speculative buy rating and headlines, “Updating model to reflect reloaded balance sheet and timing of M&A closing.” The main reason for the downgrade was due to the dilution via the financing, while they did very slightly change their full-year 2021 and 2022 revenue estimate.

Taylor believes that after the financing, the company now has on a pro-forma basis C$60 million in cash and “is well-capitalized to pursue additional M&A targets.” The company also announced that they signed a definitive agreement with IDYA4. The company did U$4.4 million in revenue with a 31% EBITDA margin in 2020. The deal is expected to close by the end of March, while Canaccord has moved back the closing date of VisionPros to late in the second quarter.

Taylor touches on the March 2nd partnership with Medavie Blue Cross. He writes, “the announcement highlights CloudMD’s increased focus on digital corporate and insurer offerings in addition to primary health services. We understand that, in recent months, CloudMD has seen success in cross-selling its broader footprint of enterprise-focused solutions to drive organic growth post-acquisition.”

Below you can see Canaccord’s slight estimate changes for the years 2021 and 2022.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Epic Gold Outlines 150,700 Indicated Ounces at 2.26 G/T in Updated Benoist Resource

Related News

Cantor Releases Industry Report For Cannabis, Aphria Remains Top Pick

Recently, Cantor Fitzgerald released their monthly review of Hifyre data for the four weeks ending...

Sunday, October 4, 2020, 01:57:00 PM

Canaccord Reiterates $1.75 Price Target For Mind Medicine Following Roadshow Event

This morning, Canaccord released a flash update for Mind Medicine (NEO: MMED) with highlights from...

Monday, September 28, 2020, 11:02:24 AM

Curaleaf Consensus Target Remains Flat After Record Quarter

On August 9, Curaleaf Holdings (CSE: CURA) reported record second quarter financial results. The company...

Tuesday, August 17, 2021, 11:43:00 AM

First Quantum: BMO Lowers Target To $32 After Guidance Issuance

On January 17th, First Quantum Minerals (TSX: FM) announced its 2021 preliminary production and 2022...

Wednesday, January 19, 2022, 04:29:00 PM

BMO Lifts Nuvei Price Target To $114

On November 9th, Nuvei Corporation (TSX: NVEI) announced its third quarter financial results. The company...

Wednesday, November 17, 2021, 03:05:00 PM